Heidi Ko: The importance of comprehensive genomic profiling in cancer of unknown primary
Heidi Ko, Medical Director, Medical Affairs,
“What an impactful study highlighting the importance of comprehensive genomic profiling (CGP) in cancer of unknown primary (CUP)
CUP accounts for about 2-3% of all metastatic cancers and encompasses diverse cancer types that do not have the usual clinicopathological features suggestive of a primary site. Patients with CUP are traditionally treated with a broad-spectrum of platinum-based chemotherapy.
CUPISCO study showed that patients with non-squamous, poorly differentiated CUP had better outcomes when treated with molecularly guided therapy from CGP than standard platinum-based chemotherapy after achieving initial disease control
Median progression-free survival nearly doubled in the group treated with targeted therapy based on genomic results (8.1 vs. 4.7 months)
CGP should be performed to assess all relevant molecular biomarkers at initial diagnosis for patients with CUP.”
Authors: Tilmann Bochtler, Prof Chantal Pauli, Kai-Keen Shiu, Natalie Cook, Juliana Janoski de Menezes, Roberto A Pazo-Cid, Ferran Losa, Debbie GJ Robbrecht, Jiří Tomášek, Prof Cagatay Arslan, Prof Mustafa Özgüroğlu, Prof Michael Stahl, Frédéric Bigot, Sun Young Kim, Yoichi Naito, Prof Antoine Italiano, Nasséra Chalabi, Gonzalo Durán-Pacheco, Chantal Michaud, Jeremy Scarato, ∙ Marlene Thomas, Prof Jeffrey S Ross, Prof Holger Moch, Linda Mileshkin.
Source: Heidi Ko/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023